Table 2.

Summary of the advantages and disadvantages of ImmTACs over other immunotherapy treatment modalities.

Advantages	Disadvantages
Ability to target peptides derived from intracellular targets	HLA restriction excludes patients
Ability to recruit non-tumour-specific T cells	On-target, off-tumour side effects with potential for significant toxicity
Can be produced on relatively large scale	Limited number of tumour-specific antigen targets so far
No pre-conditioning/prior immunosuppression required	Limited scope for preclinical testing in animal models
	Heterogeneity of target expression

HLA, human leukocyte antigen; ImmTAC, immune mobilising monoclonal T-cell receptors against cancer.